**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Heroes and pillars of rheumatology

- 435** Gerald Weissmann: Inflammation in rheumatic disease
B N Cronstein, J P Buyon, S B Abramson

Viewpoint

- 437** What is the real role of ultrasound in the management of juvenile idiopathic arthritis?
R Cimaz, T Giani, R Caporali

Rheumatoid arthritis

- 440** Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014
E Myasoedova, J Davis, E L Matteson, C S Crowson

- 445** Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?
P Studenic, D Felson, M de Wit, F Alasti, T A Stamm, J S Smolen, D Aletaha

- 453** Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
S Ramiro, R BM Landewé, D van der Heijde, A Sepriano, O FitzGerald, M Ostergaard, J Homik, O Elkayam, J C Thorne, M Larche, G Ferracioli, M Backhaus, G Boire, B Combe, T Schaeferbeke, A Saraux, M Dougados, M Rossini, M Govoni, L Sinigaglia, A G Cantagrel, C F Allaart, C Barnabe, C O Bingham, P P Tak, D van Schaardenburg, H B Hammer, R Dadashova, E Hutchings, J Paschke, W P Maksymowych

- 460** Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy
M Safy-Khan, J W G Jacobs, M J H de Hair, P M J Welsing, M D Edwardes, X M Teitsma, Y Luder, J Devenport, J M van Laar, A Pethoe-Schramm, J W J Bijlsma

- 464** Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
P Emery, S Horton, R B Dumitru, K Naraghi, D van der Heijde, R J Wakefield, E M A Hensor, M H Buch

- 472** Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
T Kissel, S Reijm, LM Slot, M Cavallari, CM Wortel, RD Vergoesen, G Stoeken-Rijsbergen, JC Kwekkeboom, ASB Kampstra, EWN Levarht, JW Drijfhout, H Bang, KM Bonger, GMC Janssen, PA van Veelen, TWJ Huizinga, HU Scherer, M Reth, REM Toes

- 481** Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling
L Godmann, M Bollmann, A Korb-Pap, U König, J Sherwood, D Beckmann, K Mühlenberg, F Echtermeyer, J Whiteford, G De Rossi, T Pap, J Bertrand

Psoriatic arthritis

- 490** GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
E Vieira-Sousa, P Alves, A M Rodrigues, F Teixeira, J Tavares-Costa, A Bernardo, S Pimenta, F Pimentel-Santos, J L Gomes, R Aguiar, P Pinto, T Videira, C Caitta, H Santos, J Borges, G Sequeira, C Ribeiro, L Teixeira, P Ávila-Ribeiro, F M Martins, H Canhã, I McInnes, R M Ribeiro, J E Fonseca

- 499** Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
M Souto-Carneiro, L Tóth, R Behnisch, K Urbach, K D Klika, R A Carvalho, H-M Lorenz

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
J.M00004


This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it


Systemic sclerosis

- 507** Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH
 OPEN ACCESS
C W Wasson, G Abignano, H Hermes, M Malaab, R L Ross, S A Jimenez, H Y Chang, C A Feghali-Bostwick, F del Galdo

Sjögren's syndrome

- 518** Elevated EPST11 promote B cell hyperactivation through NF- κ B signalling in patients with primary Sjögren's syndrome
J Sun, H Zhang, S Liu, C Lian, Z Chen, T Shao, S Zhang, L Zhao, C He, M Wang, W Zhang, H Chen, F Zhang


Osteoarthritis

- 525** Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial
 OPEN ACCESS
F Eckstein, J L Kraines, A Aydemir, W Wirth, S Maschek, M C Hochberg

Crystal arthropathies

- 529** Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data
J A Singh, J D Cleveland
- 536** Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
V Klück, R C van Deuren, G Cavalli, A Shaikat, P Arts, M C Cleophas, T O Crişan, A-K Tausche, P Riches, N Dalbeth, L K Stamp, J H Hindmarsh, T L T A Jansen, M Janssen, M Steehouwer, S Lelieveld, M van de Vorst, C Gilissen, L Dagna, F L Van de Veerdonk, E Z Eisenmesser, S Kim, T R Merriman, A Hoischen, M G Netea, C A Dinarello, L A B Joosten

Letters

- 546** Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
 OPEN ACCESS
C Rogier, S Hayer, A van der Helm-van Mil

- 547** Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study
M Yates, R Welikala, A Rudnicka, T Peto, A J MacGregor, A Khawaja, R Watts, D Broadway, S Hayat, R Luben, S Barman, C Owen, K-T Khaw, P Foster

- 549** Dupilumab as a novel steroid-sparing treatment for IgG4-related disease
R S Simpson, S K C Lau, J K Lee

Electronic pages

- e36** 'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?
M Scherlinger, T Schaefferbeke
- e37** Response to "To switch or not to switch": the missing piece in the puzzle of biosimilar literature?' by Scherlinger *et al*
B Glinborg, A G Loft, E Omerovic, O Hendricks, A Linauskas, J Espesen, K Danebod, D V Jensen, H Nordin, E B Dalgaard, S Chrysidis, S Kristensen, J L Raun, H Lindegaard, N Manilo, S H Jakobsen, I M J Hansen, D D Pedersen, I J Sørensen, L S Andersen, J Grydehøj, F Mehnert, N S Krogh, M Lund Hetland
- e38** When binary and continuous responses disagree
F Ouyang
- e39** Response to: 'When binary and continuous responses disagree' by Dr Ouyang
K Lauper, D S Courvoisier, C Gabay
- e40** Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis
Z S Wallace, H Choi, J H Stone
- e41** Response to: 'Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis' by Wallace *et al*
A Kronbichler, J Kerschbaum
- e42** Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis
M Cutolo, S Soldano, S Paolino
- e43** Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo *et al*
S Aungier, A J Cartwright, A Schwenger, J Marshall, M R Dyson, P Slavny, K Parthiban, A Karatt-Vellatt, I Sahbudin, E Culbert, P Hextall, F IL Clancy, R Williams, B D Marsden, K Raza, A Filer, C D Buckley, J McCafferty, K S Midwood

- e44** Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar
J Kay, T Dörner, P Emery, T K Kvien, F C Breedveld
- e45** 'Everything we see is a perspective, not the truth'
A Chattopadhyay, V Dhir, S Jain
- e46** Response to 'Everything we see is a perspective, not the truth' by Chattopadhyay *et al*
A Molto, J Sahuguet, J Fechtenbaum, A Etcheto, C López-Medina, P Richette, M Dougados, C Roux, K Briot
- e47** IgA vasculitis in adults: few certainties and many uncertainties
A Hočevar, M Tomšič, Ž Rotar
- e48** Response to 'IgA vasculitis in adults: few certainties and many uncertainties' by Hočevar *et al*
A Tracy, A Subramanian, N J Adderley, L Harper, K Nirantharakumar